Clinical trials: Oral Anticancer Drugs
Breast Cancer
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called ARV-471) when given together with other medicines for the potential treatment of advanced or metastatic breast cancer.
- Trial name
- NCT05548127
- Testing
- ARV-471, Abemaciclib
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
Cancer, Oral Anticancer Drugs
ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE
As the proportion of oral anticancer treatments is continuously increasing, adherence appears as a major issue for patients' outcomes.
- Trial name
- ADOPT-PRESTAGE (NCT03296150)
- Testing
- PRESTAGE
- Where
- 9 sites in France
- Volunteers
- 139 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumours
Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the effect of rifampicin on the PK parameters of olaparib in patients; Part B will allow patients continued access to olaparib after the PK…
- Trial name
- NCT01929603
- Testing
- Pharmacokinetic sampling, Rifampicin, Olaparib tablet dosing
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Cancer
Medico-economic Evaluation of the ONCORAL Program for Ambulatory Patients Under Oral Anticancer Drugs Versus Usual Care
Economic impact of cancer treatments is increasing for years: increase of number of patients (385 000 new occurrences in 2015), increase of life expectancies, chronicization of diseases and increase of therapeutic innovation…
- Trial name
- ONCORAL-PRME (NCT03660670)
- Testing
- ONCORAL therapeutic education, Standard of care
- Where
- France
- Volunteers
- 215 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumours
To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
This is a 3 part study for patients with solid tumours. The purpose of Part A is to measure the amount of olaparib or its breakdown products in the bloodstream for up to 72 hours after eating and the effect of olaparib on QT…
- Trial name
- NCT01921140
- Testing
- Olaparib tablets, Pharmacokinetic sampling, Dietary Fasted
- Where
- 12 sites in Belgium, Denmark and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Breast Cancer, ALL
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
This study aims to develop, implement and evaluate a care pathway for patients with cancer who are treated with oral anticancer drugs (OACD).
- Conditions
- Breast Cancer, ALL, Lung Cancer, Melanoma
- Trial name
- CONTACT (NCT02861209)
- Testing
- Implementation of a care pathway
- Where
- 4 sites in Belgium
- Volunteers
- 228 people
- Sponsor
- KU Leuven
Cancer
Pazopanib Tolerability When Given With Food
Pazopanib (Votrient) is registered for the treatment of patients with advanced renal cell carcinoma and patients with soft tissue sarcoma who have received prior chemotherapy.
- Trial name
- DIET (NCT02138526)
- Testing
- pazopanib, continental breakfast
- Where
- Netherlands
- Volunteers
- 78 people
- Sponsor
- Radboud University Medical Center
Solid Tumor, Hematologic Malignancy
Implementation of an Oral Chemotherapy Adherence Intervention
The goal of this study is to evaluate the effectiveness and usability of a newly developed oral anticancer agent adherence program implemented across 6 cancer clinics (two academic, two urban, and two rural).
- Trial name
- NCT06989489
- Testing
- Multilevel Adherence Intervention
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adults, Hematological Malignancy
A Mixed Method to Study Adherence to Oral Anticancer Medications in a Multilingual and Multicultural Setting
Patients with haematologic malignancies are increasingly treated by Oral Anticancer Medications (OAMs), increasing the challenge of ensuring optimal adherence to treatment.
- Conditions
- Adults, Hematological Malignancy, Oral Antineoplastic Agents
- Trial name
- MADESIO (NCT04613765)
- Testing
- Measure adherence behaviors
- Where
- 2 sites in Belgium
- Volunteers
- 113 people
- Sponsor
- Jules Bordet Institute
Non Small Cell Lung Cancer
Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02908750
- Testing
- Fexofenadine tablet dosing, Osimertininb tablet dosing
- Where
- 7 sites in France, South Korea and 1 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Cancer, Oncology
PACOME (PAtient Cancer Oral MEdication) Cohort of Patients Treated With Oral Anticancer Drugs Benefiting From Oncoral Multidisciplinary Monitoring in Real Life: Predictive Factors and Safety of Treatments
With the shift to ambulatory care and the rise of ATCO oral anticancer drugs, a growing number of cancer patients are benefiting from oral treatment in an outpatient setting, which meets their needs and preference over injectable…
- Conditions
- Cancer, Oncology, Oncoral Program
- Trial name
- PACOME (NCT06317389)
- Testing
- Questionnaires
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Hospices Civils de Lyon
Solid Tumours
To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours
This is a 3-part study in patients with advanced solid tumours: Part A will assess the effect of itraconazole on the PK parameters of olaparib and will determine the effect of olaparib on the QT interval following single oral…
- Trial name
- NCT01900028
- Testing
- Pharmacokinetic sampling, Olaparib tablet dosing, Itraconazole
- Where
- 14 sites in Belgium, Denmark and 2 more
- Volunteers
- 85 people
- Sponsor
- AstraZeneca
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate renal impairment compared to patients with normal renal function; Part B will allow…
- Trial name
- NCT01894256
- Testing
- Olaparib tablet dosing
- Where
- 13 sites in Belgium, Denmark and 3 more
- Volunteers
- 56 people
- Sponsor
- AstraZeneca
Cancer, Cancer, Treatment-Related
Oncotool for Cancer Medications
The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, TKI adherence and health related quality of life (HRQoL), in patients taking TKIs for cancer…
- Conditions
- Cancer, Cancer, Treatment-Related, Medication Adherence, Communication
- Trial name
- NCT03952312
- Testing
- Oncotool Intervention (symptom reporting + TKI education), Oncotool Control (health information)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Northwestern University
Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment
Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment
Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications.
- Conditions
- Multidisciplinary Consultation Program, Adherence to Oral Anticancer Treatment, Drug Related Toxicity, Securing Medication Management
- Trial name
- IMPAM (NCT04797143)
- Testing
- multidisciplinary consultation program
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens